Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Downgraded by BidaskClub

BidaskClub downgraded shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) from a sell rating to a strong sell rating in a research note issued to investors on Friday, October 27th.

Other analysts also recently issued research reports about the stock. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the stock a buy rating in a research report on Friday, July 7th. Aegis restated a buy rating and issued a $14.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, July 18th. Zacks Investment Research upgraded Inovio Pharmaceuticals from a hold rating to a buy rating and set a $8.75 price target for the company in a report on Tuesday, July 11th. Citigroup Inc. began coverage on Inovio Pharmaceuticals in a report on Friday, October 6th. They issued a buy rating and a $10.00 price target for the company. Finally, Royal Bank Of Canada initiated coverage on Inovio Pharmaceuticals in a report on Wednesday, October 18th. They issued an outperform rating and a $11.00 price target for the company. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of Hold and an average target price of $19.16.

Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at $4.31 on Friday. Inovio Pharmaceuticals has a 1 year low of $4.20 and a 1 year high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The business had revenue of $2.60 million during the quarter, compared to analysts’ expectations of $10.27 million. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. Inovio Pharmaceuticals’s quarterly revenue was down 79.2% on a year-over-year basis. equities research analysts predict that Inovio Pharmaceuticals will post -1.08 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://ledgergazette.com/2017/11/15/inovio-pharmaceuticals-inc-ino-downgraded-by-bidaskclub.html.

The firm also recently declared a monthly dividend, which was paid on Monday, October 16th. Stockholders of record on Friday, September 29th were issued a dividend of $0.069 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 19.21%. The ex-dividend date was Thursday, September 28th.

Institutional investors and hedge funds have recently modified their holdings of the company. Wasatch Advisors Inc. increased its holdings in shares of Inovio Pharmaceuticals by 43.6% during the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock valued at $20,469,000 after purchasing an additional 793,306 shares during the period. Wells Fargo & Company MN boosted its stake in Inovio Pharmaceuticals by 28.9% during the first quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock valued at $825,000 after buying an additional 27,898 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Inovio Pharmaceuticals by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock valued at $2,266,000 after buying an additional 11,765 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Inovio Pharmaceuticals by 9.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 334,017 shares of the biopharmaceutical company’s stock valued at $2,619,000 after buying an additional 28,173 shares in the last quarter. Finally, Ark Investment Management LLC boosted its stake in Inovio Pharmaceuticals by 79.2% during the second quarter. Ark Investment Management LLC now owns 65,901 shares of the biopharmaceutical company’s stock valued at $517,000 after buying an additional 29,128 shares in the last quarter. 24.98% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply